Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 10Neoplasms 3Keratosis, Actinic 3Skin Diseases 2Preleukemia 2Obesity-Related Malignant Neoplasm 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Leukemia 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Diseases 2Endometrial Neoplasms 2Bone Marrow Diseases 2Venentoclax 1Uterine Prolapse 1Uterine Cervical Neoplasms 1Syndrome 1Stomach Neoplasms 1Rectal Malignant Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Processes 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Multiple Myeloma 1Metrorrhagia 1Menstruation Disturbances 1

Interventions

venetoclax 1fludarabine 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Venentoclax × Other neoplasm × 90 days × Clear all
NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

First Affiliated Hospital of Zhejiang University

Phase 3 Recruiting
186 enrolled
Other neoplasm

Venentoclax

Data powered by HemOnc (CC BY 4.0) Colophon âš¡